AMSTERDAM (Reuters) – Europe’s medicines watchdog on Tuesday said the benefits of AstraZeneca’s COVID-19 vaccine continue to outweigh the risks after several countries halted its use due to concerns about blood clots.
The EMA’s Executive Director Emer Cooke said the agency was carrying out a case-by-case evaluation of incidents and was expected to complete a review on Thursday.
(Reporting by Anthony Deutsch; Editing by Catherine Evans)
